TGA Testing Found Unapproved Peptide Labels Did Not Match Their Contents (Nov 5, 2026)

Biohacking Elite logo

Published by Biohacking Elite · Updated November 13, 2026. No independent specialist review is claimed.

On November 5, 2026, Australia’s TGA reported that laboratory testing of certain unapproved Synedica-branded peptide products found they did not contain what their labels claimed. The alert concerns those tested products. It is not a survey of all peptide labels, and it does not involve Biohacking Elite’s catalog.

What this action is

The Therapeutic Goods Administration safety alert states that some tested products contained no detectable TB-500, despite being labelled as containing TB-500, and that tested Synedica Retatrutide 10 mg products contained less retatrutide than stated on the label, with significant variation between samples. TGA’s published findings are:

  • Synedica BPC 157 & TB 500 10 mg — no TB-500 detected
  • Synedica KLOW 80 mg — no TB-500 detected
  • Synedica BARBIE KLOW 100 mg — no TB-500 detected
  • Synedica Retatrutide 10 mg — contained less retatrutide than stated on the label, with significant variation between samples

The alert states that KLOW is labelled as containing GHK-Cu, BPC-157, TB 500, KPV, and vitamin B12, and that BARBIE KLOW is labelled as containing GHK-Cu, melanotan I, BPC-157, TB 500, KPV, and vitamin B12. TGA’s conclusion is that consumers cannot rely on those product labels to know what substance they are taking or the amount they are receiving. The products were identified when the TGA assisted the NSW Police State Crime Command with Strike Force Antree.

TGA also states that Synedica-branded peptide products have not been assessed by the TGA for quality, safety, or efficacy, and that their place of manufacture has not been approved by the TGA. On retatrutide, the alert says the substance is still undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator, and that any retatrutide product accessed outside a clinical trial could be counterfeit.

What this action is not

The published table covers four Synedica product labels. The alert does not give a total count of individual samples and does not state a market-wide failure rate. It is not a test of other brands, and it is not a test of Biohacking Elite products. Biohacking Elite is summarizing the official alert for documentation context only. This page is not medical advice, and it does not recommend buying, using, or discarding a product; those consumer steps are stated by the TGA in the alert.

Source: TGA safety alert, published 5 November 2026.

Related verification resources

These official notices concern specific regulator findings and policies. They are not tests of Biohacking Elite’s research-use-only catalog. For a buyer-facing workflow that checks a certificate with the issuing laboratory, and for how to read test-scope claims, start here:

For additional research context, see the research library.


About this resource

Biohacking Elite — company editorial resource for laboratory research and documentation literacy. This page summarizes official regulator documents for context. It is not legal advice, medical advice, or a laboratory report, and it is not an endorsement of any compounded, approved, or unapproved drug product.

Research-use only. No medical advice, dosing, administration instructions or human-use recommendations are provided. Nothing here establishes that a research material is suitable for human or animal consumption, or that it is a compounded or approved drug.

For laboratory research use only. Not for human or veterinary use.
Scroll to Top